title: Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.
abstract: The combination of oral tegafur-uracil (UFT) with leucovorin (LV) is used to treat patients with stage II to III colon cancer based on the results of postoperative randomized studies in which UFT/LV treatment showed an equivalent efficacy to intravenous 5-FU plus LV therapy. However, whether the addition of LV to UFT can elevate the antitumor activity of UFT in colorectal tumors with high expression levels of thymidylate synthase (TS), which affects 5-FU efficacy, remains to be clarified. This study investigated the effect of LV on the antitumor activity of UFT and/or 5-FU prodrugs in low folate diet-fed nude mice using human colorectal cancer xenografts with various expression levels of TS. The addition of LV to UFT resulted in a 55-79% inhibition of tumor growth among 11 types of colorectal tumor xenograft, whereas UFT alone showed 23-67% antitumor activity. Although there was an inverse relationship between the antitumor effect of UFT alone and UFT plus LV and tumoral TS activity, UFT plus LV appeared to have a more potent antitumor effect than UFT alone on colorectal tumors such as Co-3 and KM12C/5-FU with high expression levels of TS. This finding was confirmed by the significant positive correlation between the relative inhibition ratio of UFT/LV to UFT alone and TS levels in tumors. To investigate the reason for the higher efficacy of UFT/LV on colorectal cancer xenografts with high TS activity, intratumoral levels of reduced folates and a ternary complex of TS after oral UFT with or without LV were measured using Co-3 xenografts. Elevated levels of reduced folates and an increased ternary complex of TS in LV-treated tumors were noted. Our results indicate that a combined therapy of UFT with LV may contribute to the treatment of colorectal cancer patients with low and high expression levels of tumoral TS by increased formation of the ternary complex of TS leading to potentiated antitumor efficacy of UFT.
authors.affiliation: Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima 771-0194, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tsujimoto
authors.forename: Sayaka
authors.initials: S
authors.lastname: Tsukioka
authors.forename: Satoru
authors.initials: S
authors.lastname: Ono
authors.forename: Etsuko
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Kazuki
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Kohji
authors.initials: K
authors.lastname: Tsuta
authors.forename: Fumio
authors.initials: F
authors.lastname: Nakagawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Saito
authors.forename: Junji
authors.initials: J
authors.lastname: Uchida
authors.forename: Mamoru
authors.initials: M
authors.lastname: Kiniwa
authors.forename: Masakazu
authors.initials: M
authors.lastname: Fukushima